The FDA has approved RFA for treatment of certain tumors. While RFA of tumor can be curative, it is usually palliative, extending patient’s life expectancy and improving quality of life while living with the cancer.
The procedure is performed as an outpatient in a hospital using intravenous sedation or general anesthesia. The procedure generally takes less than an hour to perform.
The tumor is usually treated in one session but may occasionally require an additional treatment. Complications are unusual and occur in about 2% of patients. These include bleeding, infection or damage to adjacent tissue or organs. RFA is considered for patients in whom surgery is not a good option or when other medical conditions increase the risk of surgery.
RFA can be used to treat a variety of tumors, both malignant and benign. Tumors involving the liver, kidney, lung, and bone can be treated. RFA is particularly effective for treatment of smaller (less than 5 cm, about 2 inches) primary cancers of the liver – called hepatocellular carcinomas or HCC. Other types of liver tumors can be treated as well. Primary cancers of the kidney, renal cell tumors, can be treated with RFA as determined by the urologist. Certain types of lung cancers can be treated by this method. Painful bone tumors, malignant and benign (osteoid osteoma) can be effectively treated with either RFA or kyphoplasty.